Carolina Garrido

Summary

Affiliation: Hospital Universitario
Country: Spain

Publications

  1. pmc Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens
    Carolina Garrido
    Hospital Carlos III, Madrid, Spain
    Antimicrob Agents Chemother 56:2873-8. 2012
  2. doi request reprint Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience
    Carolina Garrido
    Infectious Diseases Department, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Antiviral Res 90:164-7. 2011
  3. doi request reprint Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 25:967-72. 2009
  4. doi request reprint Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection
    Carolina Garrido
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:320-6. 2010
  5. doi request reprint Raltegravir and etravirine are active against HIV type 1 group O
    Veronica Briz
    Department of Infectious Disease, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 25:225-7. 2009
  6. doi request reprint Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations
    Carolina Garrido
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 28:156-64. 2012
  7. doi request reprint Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 46:1782-5. 2008
  8. pmc Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay
    Miguel Arredondo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Clin Microbiol 50:569-72. 2012
  9. doi request reprint High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists
    Eduardo Seclen
    Infectious Diseases Department, Hospital Carlos III, Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 65:1486-92. 2010
  10. ncbi request reprint [Resistance to integrase inhibitors]
    Carolina Garrido
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:40-6. 2008

Collaborators

Detail Information

Publications22

  1. pmc Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens
    Carolina Garrido
    Hospital Carlos III, Madrid, Spain
    Antimicrob Agents Chemother 56:2873-8. 2012
    ..There is broad cross-resistance between RAL and EVG, which should preclude their sequential use. Resistance to EVG seems to be more frequent and might be more influenced by integrase variability...
  2. doi request reprint Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience
    Carolina Garrido
    Infectious Diseases Department, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Antiviral Res 90:164-7. 2011
    ..T124A was more frequent in INI-naïve patients but E92Q and Q148H/R were only seen in raltegravir-experienced individuals. Thus, both HIV-1 subtype and raltegravir exposure may influence the antiviral activity of dolutegravir...
  3. doi request reprint Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 25:967-72. 2009
    ....
  4. doi request reprint Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection
    Carolina Garrido
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:320-6. 2010
    ..Little is known about the extent and predictors of polymorphisms potentially influencing the susceptibility to HIV integrase inhibitors (INIs)...
  5. doi request reprint Raltegravir and etravirine are active against HIV type 1 group O
    Veronica Briz
    Department of Infectious Disease, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 25:225-7. 2009
    ..Therefore, individuals infected with HIV-1 group O might benefit from raltegravir and/or etravirine therapy...
  6. doi request reprint Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations
    Carolina Garrido
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 28:156-64. 2012
    ..001). Undetectable RAL C(t) was seen only in patients failing RAL without integrase resistance mutations (64.1% of them). RAL failures in the absence of integrase resistance mutations mainly reflect poor drug compliance...
  7. doi request reprint Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 46:1782-5. 2008
    ..001), despite elevated and stable rates of tenofovir use. A reduction in the rate of coadministration of didanosine (from 41.6% of patients in 2004 to 0.8% of patients in 2006; P < .001) largely explained this observation...
  8. pmc Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay
    Miguel Arredondo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Clin Microbiol 50:569-72. 2012
    ....
  9. doi request reprint High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists
    Eduardo Seclen
    Infectious Diseases Department, Hospital Carlos III, Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 65:1486-92. 2010
    ..Evaluation of the reliability of several V3-based genotypic predictors to infer viral tropism in patients infected with B and non-B strains of HIV-1...
  10. ncbi request reprint [Resistance to integrase inhibitors]
    Carolina Garrido
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:40-6. 2008
    ..The most common resistance pattern seems to be E138K + E147G + Q148R. There is a high grade of cross resistance between raltegravir and elvitegravir, making sequencing between these two drugs impossible...
  11. pmc Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests
    Carolina Garrido
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    J Clin Microbiol 47:1031-6. 2009
    ..In summary, the HIV-1 load can accurately be quantified by testing DBS by either the Nuclisens or the m2000rt test, although the Nuclisens test may outperform the m2000rt test when nucleic acids are extracted manually...
  12. doi request reprint Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 48:241-4. 2008
    ..Pure X4 and X4R5 dual-tropic viruses may be recognized in approximately 15% of drug-naive HIV-1-positive patients. CCR5 antagonists are active against R5 viruses; therefore, HIV tropism should be known before their prescription...
  13. doi request reprint [Viral resistance and genetic barrier of atazanavir]
    Carmen de Mendoza
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:28-33. 2008
    ..Despite having a moderate genetic barrier when not boosted with ritonavir, the prolonged half life of ATV minimises the risk of resistance in clinical practice...
  14. doi request reprint Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir
    Carolina Garrido
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 26:551-7. 2012
    ..The relative contribution of each mechanism in CD4 restoration in patients with suppressed viremia switching antiretrovirals is unclear...
  15. ncbi request reprint Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 22:311-3. 2008
    ..Therefore, L76V does not appear to be a primary lopinavir resistance change when the drug is used in combination therapy...
  16. doi request reprint Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola
    Carolina Garrido
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 61:694-8. 2008
    ..Subtype variability may influence treatment response and selection of drug resistance mutations in HIV-positive patients on antiretroviral therapy...
  17. doi request reprint Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity
    Maria Salgado
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Clin Virol 46:173-5. 2009
    ..Due to the recent introduction of these novel inhibitors, information on the selection of resistance mutations and its phenotypic effect in this population is scarce...
  18. pmc Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes
    Carolina Garrido
    Hospital Carlos III, Sinesio Delgado 10, 28029 Madrid, Spain
    J Clin Microbiol 46:887-91. 2008
    ..In summary, while inferences of HIV-1 coreceptor usage using genotypic tools seem to be reliable for clade B viruses, their performances are poor for non-B subtypes, in which they particularly fail to detect X4 variants...
  19. doi request reprint Antiviral effect of raltegravir on HTLV-1 carriers
    Ana Trevino
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 67:218-21. 2012
    ..In vitro studies support that integrase inhibitors, such as raltegravir, may inhibit human T cell lymphotropic virus type 1 (HTLV-1) replication. However, this hypothesis has not been tested in vivo...
  20. doi request reprint New therapeutic strategies for raltegravir
    Carolina Garrido
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:218-23. 2010
    ..Altogether, the current information supports a broad use of raltegravir beyond its initial approval for antiretroviral-experienced HIV-infected patients...
  21. pmc Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy
    Gilberto Betancor
    Centro de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Cientificas and Universidad Autonoma de Madrid, Madrid, Spain
    Retrovirology 9:68. 2012
    ..In this context, we have studied the role of R284K as a secondary mutation associated with mutations of the TAM1 complex...
  22. ncbi request reprint Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 23:879-85. 2007
    ..However, broad PI cross-resistance was seen in nearly 25% of antiretroviral-experienced patients in 2005. Therefore, there is a still need for new antiretrovirals with different resistance profiles...